by Clinical Neuropsychologist | Friday, March 7, 2025 | Dementia
Abstract INTRODUCTION The ability to integrate information across sensory modalities is a vital aspect of everyday functioning and is linked to cognition. Increasing evidence suggests that Alzheimer’s disease (AD) pathology manifests in sensory association areas...
by Clinical Neuropsychologist | Thursday, March 6, 2025 | Dementia
Abstract INTRODUCTION Amyloid beta oligomers (Aβos) are toxic to synapses and key to the progression of Alzheimer’s disease (AD) and amyloid pathology, representing a target for therapeutic strategies. METHODS Amyloid and small ubiquitin modifier 2 (SUMO2)...
by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia
Abstract Virtually all people with Down syndrome will develop Alzheimer disease pathology during their lifetime. As Alzheimer disease is the third leading cause of death and a significant factor in end-of-life complications for adults with Down syndrome, identifying...
by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia
Abstract We systematically reviewed and meta-analyzed bulk RNA sequencing (RNAseq) studies comparing Alzheimer’s disease (AD) patients to controls in human brain tissue. We searched PubMed, Web of Science, and Scopus for human brain bulk RNAseq studies,...
by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia
Abstract INTRODUCTION Parkinsonism in patients with Alzheimer’s disease (AD) is often attributed to Lewy-related pathology, given its high comorbidity. In the era of anti-amyloid therapy, recognizing parkinsonism caused by AD pathology is needed to optimize the...
